Imagify™ Clinical Program Overview
Imagify has been administered to over 1,000 patients in studies conducted in the US and in Europe.
Overview of Imagify™ Pivotal Trials
- Two well-controlled non-inferiority trials (N=777)
- Imagify™ Perfusion Stress Echocardiography (PSE) results are as accurate as those with stress nuclear perfusion imaging
- Superior specificity in RAMP-1
- Superior sensitivity in RAMP-2
- 99% of images were evaluable
- Imagify™ appears to be well tolerated.
- The majority of adverse events were mild in intensity, self-limiting and resolved with no residual effects.
- No added risk for arrhythmias or other EKG changes were found.